The Journal of the American Medical Association will carry the results from the ASCENT phase IV study, which assessed the potential of Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease (COPD).
The data showed the inhaled powder was effective at combating exacerbations (worsening of the symptoms) of COPD with no increase in major cardiovascular events.
Heart disease often goes hand in hand with COPD and 30% of patients die as a result of related conditions.
The phase IV trial provided what’s called a label extension for Tudorza, which means the drug can be administered to a wider patient group.
Circassia chief executive Steve Harris said: "The publication of these clinical results in the prestigious Journal of the American Medical Association further demonstrates Tudorza's safety and efficacy, particularly in this group of at-risk patients.
“We are delighted at this recognition of the importance of these data, and of the recent inclusion of this new information in Tudorza's prescribing information."